Subscribe to Newsletter
Diagnostics Genetics and epigenetics, Omics

Breaking Bad Genetics

Some of us may have heard people say, “Addiction runs in my family.” And it’s common knowledge that substance abuse is driven by genetic, as well as environmental factors. It’s only recently, though, that a group of researchers from Boston University School of Medicine have identified a gene that demonstrates a causal relationship to addiction – specifically, to methamphetamine sensitivity (1).

“Both genes and environment can exert independent and interactive influences on an individual’s risk for developing an addiction throughout life,” explains corresponding author Camron Bryant. “Gene discovery is one important piece of the puzzle in understanding the neurobiological adaptations that confer risk versus resistance to the addictions throughout development and into adulthood.” Bryant and his colleagues employed an unbiased, discovery-based approach called quantitative trait locus (QTL) mapping in mice; they sought broad chromosomal regions causally associated with variations in sensitivity to the methamphetamine locomotor stimulant response – a behavior is associated with activation of the dopamine reward circuitry in the brain. “We honed in on a particular region of a chromosome by using a ‘fine mapping’ approach to identify the smallest possible region necessary for differential drug responding. The region we identified contained only two protein-coding genes, which we mutated to identify the causal factor.” The gene Bryant and his colleagues ultimately discovered is called heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1), which codes for an RNA-binding protein that regulates hundreds of genes in the brain.

“An obvious next step is to determine whether or not this novel factor is genetically associated with methamphetamine addiction in humans,” says Bryant. “That would strengthen the impact of our findings and could have implications for prescribing psychostimulant drugs like Adderall or Ritalin, which have similar molecular mechanisms of action to methamphetamine.” At the moment, the researchers are developing the tools to identify the brain region-specific RNA targets of hnRNP H1 and assessing its contribution to behavioral traits more closely aligned with addiction, including conditioned drug reward and self-administration of drugs of abuse. They are also extending their findings to other disease models known to be associated with dysfunction of RNA binding proteins. Gene expression analysis indicates a role in dopaminergic neuron development – meaning that hnRNP H1 may play a role not only in addiction, but in neurological disorders like ADHD, schizophrenia, and Parkinson’s disease.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. N Yazdani et al., “Hnrnph1 is a quantitative trait gene for methamphetamine sensitivity”, PLoS Genet, 11, e1005713 (2015). PMID: 26658939.
About the Author
Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

Related Application Notes
Evaluation of cell-free fetal DNA to determine fetal RhD status

| Contributed by Revvity

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Enabling Efficient, Cost-effective Sequencing of the Human Whole Exome

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine